David H. Johnson

652 total citations
12 papers, 497 citations indexed

About

David H. Johnson is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, David H. Johnson has authored 12 papers receiving a total of 497 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Oncology, 4 papers in Pulmonary and Respiratory Medicine and 3 papers in Molecular Biology. Recurrent topics in David H. Johnson's work include Lung Cancer Treatments and Mutations (3 papers), Radiopharmaceutical Chemistry and Applications (2 papers) and Cancer Diagnosis and Treatment (2 papers). David H. Johnson is often cited by papers focused on Lung Cancer Treatments and Mutations (3 papers), Radiopharmaceutical Chemistry and Applications (2 papers) and Cancer Diagnosis and Treatment (2 papers). David H. Johnson collaborates with scholars based in United States, Canada and Japan. David H. Johnson's co-authors include Carlos L. Arteaga, Rut Porta, Adriana González, David P. Carbone, F. Anthony Greco, Ben W. Davis, Kiyoshi Yanagisawa, Elsbeth Chee, Loren M. Frank and James L. Mills and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and The Journal of Pediatrics.

In The Last Decade

David H. Johnson

12 papers receiving 471 citations

Peers

Countries citing papers authored by David H. Johnson

Since Specialization

Citations

This map shows the geographic impact of David H. Johnson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David H. Johnson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David H. Johnson more than expected).

Fields of papers citing papers by David H. Johnson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David H. Johnson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David H. Johnson. The network helps show where David H. Johnson may publish in the future.

Co-authorship network of co-authors of David H. Johnson

This figure shows the co-authorship network connecting the top 25 collaborators of David H. Johnson. A scholar is included among the top collaborators of David H. Johnson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David H. Johnson. David H. Johnson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

#	Work	Indexed citations
1	Lipid packing defects are necessary and sufficient for membrane binding of α-synuclein 2025 ·Communications Biology ·David H. Johnson, (unknown), John White, (unknown), (unknown), (unknown), Vance Jaeger, Wade F. Zeno	2
2	Inhibition of Epidermal Growth Factor Receptor Signaling Elevates 15-Hydroxyprostaglandin Dehydrogenase in Non–Small-Cell Lung Cancer 2007 ·Cancer Research ·Li Yang, Joseph M. Amann, Takefumi Kikuchi, Rut Porta, Marta Guix, Adriana González, Ki Hun Park, Dean Billheimer, Carlos L. Arteaga, Hsin-Hsiung Tai, Raymond N. DuBois, David P. Carbone, David H. Johnson	50
3	Host and Direct Antitumor Effects and Profound Reduction in Tumor Metastasis with Selective EP4 Receptor Antagonism 2006 ·Cancer Research ·(unknown), Yuhui Huang, Rut Porta, Kiyoshi Yanagisawa, Adriana González, Eri Segi‐Nishida, David H. Johnson, Shuh Narumiya, David P. Carbone	87
4	Tyrosine kinase inhibitors—ZD1839 (Iressa) 2001 ·Current Opinion in Oncology ·Carlos L. Arteaga, David H. Johnson	146
5	Staging Lung Carcinoma with a Tc-99m Labeled Monoclonal Antibody 1992 ·Clinical Nuclear Medicine ·Johnathan P. Vansant, David H. Johnson, (unknown), James R. Stewart, A H Sonin, Barry McCook, Thomas A. Powers, Darrell Salk, William H. Frist, Martin P. Sandler	21
6	Changes inPetCO2 and pulmonary blood flow after bronchial occlusion in dogs 1992 ·Canadian Journal of Anesthesia/Journal canadien d anesthésie ·David H. Johnson, P Chang, (unknown), (unknown), Scott A. Lang, Irvin Mayers	8
7	Poorly differentiated carcinoma of unknown primary site: clinical usefulness of immunoperoxidase staining. 1991 ·Journal of Clinical Oncology ·John D. Hainsworth, Edward Wright, David H. Johnson, Ben W. Davis, F. Anthony Greco	46
8	Congenital malformations and psychosocial development in children conceived by in vitro fertilization 1989 ·The Journal of Pediatrics ·(unknown), Frederick H. Wirth, David H. Johnson, Loren M. Frank, (unknown), (unknown), Elsbeth Chee, James L. Mills	82
9	Technetium-99m labeled NR-LU-10 monoclonal antibody (MoAb) in assessing patients with carcinoma of the lung 1989 ·John Vansant, David H. Johnson, (unknown), Barry McCook, John D. Hainsworth, A H Sonin, (unknown), K. Sullivan, Darrell Salk, Paul G. Abrams	1
10	Serum neuron‐specific enolase in metastatic merkel cell tumors 1985 ·Medical and Pediatric Oncology ·Leonard Giannone, David H. Johnson, William W. Grosh, Ben W. Davis, Paul J. Marangos, F. Anthony Greco	27
11	Jugular Foramen Syndrome as a Complication of Metastatic Cancer of the Prostate 1984 ·Southern Medical Journal ·(unknown), David H. Johnson	17
12	323. The synthesis of N-alkyl-2-oxocyclopentanecarboxyamides 1958 ·Journal of the Chemical Society (Resumed) ·David H. Johnson	10

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact